Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study
2017 ASCO Annual Meeting
Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)
Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)
Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses highlights of three important abstracts on advanced and metastatic urothelial cancer presented at the 2017 ASCO Annual Meeting. (Abstracts 4501, 4503, 106)
Gerhardt Attard, MD, PhD, of The Royal Marsden Hospital and The Institute of Cancer Research, discusses trial results on continued enzalutamide post prostate-specific antigen progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer. (Abstract 5004)
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, exchange views on the key papers in renal cell carcinoma presented at ASCO’s 2017 nonprostate GU oral abstract session. (Abstracts 4504, 4505, 4506, 4507, 4508)